Clinical, histopathological and bacteriological study of 52 referral MB cases relapsing after MDT

Leprosy Review

Volumn 76, Issue 3, 2005, Pages 241-252

  Shetty, V P ^a   Wakade, A V ^a   Ghate, S D ^b   Pai, V V ^b   Ganapati, R R ^b   Antia, N H ^a  

^a FOUNDATION FOR MEDICAL RESEARCH   (India)

^b Bombay Leprosy Project   (India)

Author keywords

[No Author keywords available]

Indexed keywords

OFLOXACIN; RIFAMPICIN; LEPROSTATIC AGENT;

ADULT; ARTICLE; BORDERLINE LEPROSY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEPROMATOUS LEPROSY; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM LEPRAE; RELAPSE; SKIN TEST; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION; DRUG COMBINATION; ISOLATION AND PURIFICATION; LEPROSY; MICROBIOLOGY; PATHOLOGY; RECURRENT DISEASE;

DRUG THERAPY, COMBINATION; HUMANS; LEPROSTATIC AGENTS; LEPROSY; MYCOBACTERIUM LEPRAE; RECURRENCE;

EID: 27744537189     PISSN: 03057518     EISSN: 03057518     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. WHO leprosy unit, division of control of tropical diseases. Risk of relapse in leprosy. WHO document (WHO/CTD/LEP/94.1). WHO, Geneva, 1994.
2. Waters MFR. Relapse following various types of multidrug therapy in multibacillary leprosy (Editorial). Lepr Rev, 1995; 66: 1-9.
3. Girdhar BK, Girdhar A, Kumar A. Relapses in multibacillary leprosy patient: effect of length of therapy. Lepr. Rev, 2000; 71: 144-153.
4. Jamet P, Ji B. Marchoux chemotherapy study group. Relapse after long-term follow up of multibacillary patient treated by WHO multidrug regimen. Int J Lepr, 1995; 63: 195-201.
5. Cellona RV, Balagon MVF, Dela curz EC et al. Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients. Int J Lepr, 2003; 71: 308-319.
6. Gebre S, Sunderson P, Byss P. Relapses after fixed duration multiple drug therapy: the AMFES cohort. Lepr Rev, 2000; 71: 325-331.
7. Jesudasan K, Vijayakumaran P, Manimozhi N et al. Absence of relapse within 4 years among 34 multibacillary patients with high BIs treated for 2 years with MDT. Int J Lepr, 1996; 64: 133-135.
8. Shaw IN, Natarajan MM, Rao GS et al. Longterm follow-up of multibacillary leprosy patients with high BI treated with WHO/MDT regimen for a fixed duration of two years. Int J Lepr, 2000; 68: 405-409.
9. Ji B. Does there exist a subgroup of MB patients at greater risk of relapse after MDT? (Editorial). Lepr Rev, 2001; 72: 3-7.
10. Ridley DS, Jopling WH. Classification of leprosy according to immunity; a five group system. Int J Lepr, 1966; 34: 255-273.
11. World Health Organization. Laboratory techniques for leprosy CDS/LEP 86.4. World Health Organization, Geneva, 1987.
12. Shetty VP, Wakade AV, Ghate S et al. Viability and drug susceptibility testing of M. leprae using mouse footpad in 37 relapse cases of leprosy. Int J Lepr, 2003; 71: 210-217.
13. World Health Organization. Chemotherapy of leprosy. WHO technical report series no. 874, 1994.
14. Ganapati RR, Pai VV, Shroff HJ, Gandewar K. Rate of decline in bacterial index in leprosy; observations after three different chemotherapeutic interventions. Int J Lepr, 1997; 65: 264-265.
15. Shetty VP, Wakade AV, Antia NH. A high incidence of viable Mycobacterium leprae in post-MDT recurrent lesions in tuberculoid leprosy patients. Lepr Rev, 2001; 72: 337-344.
16. Pattyn SR, Groenen G, Bourland J et al. The incubation time of relapses after treatment of multibacillary leprosy with rifampicin containing regimens. Eur J Epidemiol, 1988; 4: 231-234.
17. Shetty VP, Suchitra K, Uplekar MW, Antia NH. Persistence of Mycobacterium leprae in the peripheral nerve as compared to the skin of multidrug-treated leprosy patients. Lepr Rev, 1992; 63: 329-336.
18. Ji B, Jamet P, Sow S et al. High relapse rates among lepromatous leprosy patients treated with rifampin plus ofloxacin daily for 4 weeks. Antimicrob Agents Chemother, 1997; 41: 1953-1956.
19. Ramu G, Desikan KV. Reactions in borderline leprosy. Ind J Lepr, 2002; 74: 115-128.
20. Pearson JMH, Rees RJW, Waters MFR. Sulphone resistance in leprosy. A review of one hundred proven cases. Lancet, 1975; 2: 69-72.
21. Pearson JMH, Cap JA, Haile GS, Rees RJW. Dapsone-resistant leprosy and its implications for leprosy control programmes. Lepr Rev, 1977; 48: 83-94.
22. Srinivasan H, Rao KS, Iyer CGS. Discrepancy in the histopathological features of leprosy lesions in the skin and peripheral nerve - report of a preliminary study. Ind J Lepr, 1982; 54: 275-282.
23. Waters MFR, Ridley DS. Tuberculoid relapse in lepromatous leprosy. Lepr Rev, 1990; 61: 353-365.
24. Ministry of Health and Family Welfare, Directorate General of Health Services (Leprosy Division), Government of India. Modified guidelines on MDT regimen to be followed under NLEP no.1.19025/6/97-Lep; Nirman Bhawan, New Delhi, 1997, pp. 1-10.
25. World Health Organization. WHO expert committee on Leprosy, Seventh Report.WHO technical report series no. 874, World Health Organization, Geneva, 1998.